Lantheus Holdings' F-18 PET radiotracer LMI 1195 resulted in similar cardiac sympathetic innervation measurements and improved early cardiac imaging kinetics, compared with C-11 hydroxyephedrine, in a midstage trial. "We believe LMI 1195 may represent a first-in-class agent and useful diagnostic tool for a significant population of patients at risk for sudden cardiac death," said Dr. Cesare Orlandi of Lantheus Medical Imaging.
Data show positive results for Lantheus' cardiac PET radiotracer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.